Fludarabine

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
In DMSO USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Br J Cancer, 2018, 118(4):509-521. Fludarabine purchased from Selleck.

    ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

  • Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

    Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

  • Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  NXH6R5VHTnWwY4Tpc44hSXO|YYm= NUjmRmxrOjBizszN MoLzNlQhcA>? NHztc4hqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIFnEUy=> MlTQNlU6PDB5MUK=
MV-4-11 M2PsUGFxd3C2b4Ppd{BCe3OjeR?= NGLBeXgzNjVizszN MoO2OFghcA>? MVvpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NE\LSGczPTFzMUW4Ny=>
THP-1 MVTBdI9xfG:|aYOgRZN{[Xl? Mn7mNk42KM7:TR?= MVG0PEBp NUi5XJNIcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MlnBNlUyOTF3OEO=
MOLM 13 MonIRZBweHSxc3nzJGF{e2G7 MoLsNk42KM7:TR?= NF\USII1QCCq NI\CfIRqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NFLjfWwzPTFzMUW4Ny=>
KBM3/Bu2506 MXfBdI9xfG:|aYOgRZN{[Xl? NVexNnhmOi53IN88US=> NYjkWZhXPDhiaB?= NGjKOllqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> Mni5NlUyOTF3OEO=
Nalm-6 NVTIT492T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO4TWM2OD1zODFOwG0> M{WwbFI2ODZzMUCx
Reh MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnsdYY2UUN3ME2zNEDPxE1? MlrQNlUxPjFzMEG=
U2937 NGPU[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rJUGlEPTB;MU[g{txO NIDQWm4zPTB4MUGwNS=>
Mec-1 NVPTcYdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\mZndKSzVy78{eOVAxKM7:TR?= MoO3NlUxPjFzMEG=
RPMI-8226 M1zSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzWTWM2OD13MECg{txO NHi3Wo4zPTB4MUGwNS=>
Molt-4 NXy1VVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF6MDFOwG0> Moq0NlUxPjFzMEG=
Nalm-6-FluR NFL2boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJ3MDFOwG0> NWC3d20zOjVyNkGxNFE>
Raji  MkHnSpVv[3Srb36gRZN{[Xl? MmrGN:Kh|ryP M1;Se|I1NzR6L{eyJIg> NGO2SYFqdmS3Y3XzJIFk[3WvdXzheIlwdnNib3[gdFU{NCCyNkOgZY5lKHB5M9Mg MUeyOFk1ODZ7NR?=
PBMC Mn\DSpVv[3Srb36gRZN{[Xl? NHHTXI42OC9zMECg{txO M2LBdVI1KGh? NWLObJFVTE2VTx?= M37MO4lvcGmkaYTzJHNVSVRzIIDoc5NxcG:{eXzheIlwdg>? NVjFPG1UOjR7MUG4O|I>
MDA-231 MXfGeY5kfGmxbjDBd5NigQ>? MWCxNFAh|ryP NYDxdnd1OjRiaB?= M{nIOWROW09? M2P3S4Rm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?= MUKyOFkyOTh5Mh?=
624.38mel  MX\GeY5kfGmxbjDBd5NigQ>? MXW1NEDPxE1? M1LONFI1KGh? MWTEUXNQ NXXGPFdq\GWlcnXhd4V{KEmGTzDlfJBz\XO|aX;u MkKxNlQ6OTF6N{K=
MDA-231 MX7GeY5kfGmxbjDBd5NigQ>? M2XkNFUxNTJyMDFOwG0> M3TZdlI1KGh? MmTtSG1UVw>? NIDVeYFqdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?= NWnZeJNsOjR7MUG4O|I>
624.38mel  M370NWZ2dmO2aX;uJGF{e2G7 NXzkW5RnPTBvMkCwJO69VQ>? NHr3U3gzPCCq MXnEUXNQ M4jzVolvcGmkaYTzJGlFVyCjY4Tpeol1gSCrbnTldIVv\GWwdHz5JI9nKG2UTlGgcIV3\Wy| MnrMNlQ6OTF6N{K=
HMECs MlP1SpVv[3Srb36gRZN{[Xl? NHHwPZEyODEEoN88UeKh NWK1Znl1OzcEoHi= MmnQbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> NGHzNmIzPDJzMUOyOy=>
HMECs  NITFXW5HfW6ldHnvckBCe3OjeR?= NHL4co0yODEEoN88UeKh M3zwclM3yqCq M3fBNYlvcGmkaYTzJGlHVs7zwrDt[YRq[XSnZDDwbI9{eGixconsZZRqd25ib3[gV3RCXDFiYX7kJHNVSVR|LDDieZQhdm:2IH;mJHNVSVR{ MV2yOFIyOTN{Nx?=
BJAB M37GOGFxd3C2b4Ppd{BCe3OjeR?= MWe1xsDPxE1? MVSyOEBp NFG5[WNqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHvjXlIzPDB3N{G0Oy=>
I-83 NUXEWYJ5SXCxcITvd4l{KEG|c3H5 M4\mUVXDqM7:TR?= M4fzZlI1KGh? MV3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUOwNnR[OjRyNUexOFc>
NALM6 MYfBdI9xfG:|aYOgRZN{[Xl? MUi1xsDPxE1? MYiyOEBp M3Tzb4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NYe3dpliOjRyNUexOFc>
DU-145 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjnR2QxNTFyIN88[{9udA>? NYroZ5BRPDhiaNMg MmO2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVfUeo91OjN5M{S4NVU>
Nalm-6 NXj2c4VkTnWwY4Tpc44hSXO|YYm= NGPxTYEyOMLizszN MY[xM|IwPCCq M1PZOYlv\HWlZYOgZZV1d3CqYXf5 NYD4PXpuOjN4OEGyNlM>
Reh MWHGeY5kfGmxbjDBd5NigQ>? MmTSNVDDqM7:TR?= MVOxM|IwPCCq M4K3U4lv\HWlZYOgZZV1d3CqYXf5 NET3PW0zOzZ6MUKyNy=>
Nalm-6 NFXJTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe1cllbUUN3MDFijNwyOOLCid88US=> NHyxS48zOzZ6MUKyNy=>
Reh MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxKOLKvEGw5qCK|ryP MmDKNlM3QDF{MkO=
HEC1A MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj4WppZOTByLUWwNEDPxE1? NXHLeWFDOjRiaB?= Ml;ZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXeyN|U6PTZ7Nx?=
AN3CA M4HhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKxNFAuPTByIN88US=> NXLNWJZ3OjRiaB?= M3j6c4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MX2yN|U6PTZ7Nx?=
HEC50B MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\hNVAxNTVyMDFOwG0> NHLhZZozPCCq NYfqTmJGcW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? Mor6NlM2QTV4OUe=
HEC1A M{fpVWFxd3C2b4Ppd{BCe3OjeR?= MVGyNE8yODBizszN NYS3WJhZOjRiaB?= NH\FcndqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmrtNlM2QTV4OUe=
AN3CA NVX5UWZ1SXCxcITvd4l{KEG|c3H5 Ml3wNlAwOTByIN88US=> NFTONIgzPCCq MnjHbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NH\idG4zOzV7NU[5Oy=>
HEC50B NX3HVmRISXCxcITvd4l{KEG|c3H5 M4m4T|IxNzFyMDFOwG0> NWPrPFZ6OjRiaB?= MVXpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NWHldnZkOjN3OUW2PVc>
EHEB MVrBdI9xfG:|aYOgRZN{[Xl? MnfEOFAh|ryP MlLwNlQhcA>? Moe5bY5lfWOnczDhdI9xfG:|aYO= NWOwVlVlOjN2OUewO|U>
A549 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\BOpNYUUN3ME2xOU44yrF{LkigxtVO NGf4bXQzOzN5N{G5Ni=>
A549 GAPDH-deficient Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF6LkZCtVIvOyEEtV2= NITQeIozOzN5N{G5Ni=>
CLL  M{m2V2Fxd3C2b4Ppd{BCe3OjeR?= MYixNEDPxE4EoB?= MWqyOE06PiCq NGTNR|lqdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NGjQWlMzOjJyN{[4Oi=>
MEC1 NUO1XY1NSXCxcITvd4l{KEG|c3H5 NWHKPVN3OTBywrFOwG0> NXjLdVdVPzJiaB?= MW\pcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 M1OwO|IzOTN{OUez
U937  NFKxV|RCeG:ydH;zbZMhSXO|YYm= NXvQNpd5OC56IN88US=> M4XjbVQuPDhiaB?= MVnpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MWOyNlA4PDdyMB?=
U937  M{nWSWFxd3C2b4Ppd{BCe3OjeR?= MUKxJO69VQ>? M4PyXFk3KGh? NELPVVdqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NFHUdnozOjB{M{WyNy=>
Daudi NIPQRo5CeG:ydH;zbZMhSXO|YYm= M3LFR|IxKM7:TR?= MYG5OkBp NX7rfIh2cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M33yflIzODJ|NUKz
J45.01 NH\5TYJCeG:ydH;zbZMhSXO|YYm= Mo\UNUDPxE1? MmHRPVYhcA>? MXjpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MmPaNlIxOjN3MkO=
RPMI 8226 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L4OGlEPTB;MkWuPeKhyrIEoEOuO{DPxE1? NULKe5NDOjF7NEiyOlQ>
CEM MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnaWHFKSzVyPUKuOOKhyrIEoECuOEDPxE1? MWWyNVk1QDJ4NB?=
Raji MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDhTWM2OD1yLkS3xsDDucLiMD6wOEDPxE1? MmD3NlE6PDh{NkS=
U937 NGC0[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv6TWM2OD1yLkK0xsDDucLiMD6wOEDPxE1? MYiyNVk1QDJ4NB?=
K562 NY\VVHRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3md2hnUUN3ME2wMlQ1yqEEsdMgNE4xPSEQvF2= Mn:wNlE6PDh{NkS=
NALM-6 MYDBdI9xfG:|aYOgRZN{[Xl? NWD4T|VlOTBizszNxsA> M136OFI1KGh? M{Pwdolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? NYO4dVdvOjF4OUmzPFM>
JMV-3 MUDBdI9xfG:|aYOgRZN{[Xl? NVHacZRtOTBizszNxsA> MUWyOEBp NWnxPVVWcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?= NXXFN45mOjF4OUmzPFM>
EHEB MkftSpVv[3Srb36gRZN{[Xl? NWPET2dxPS13MDFOwG0> NWC5eog2OjRiaB?= M3;PbYRm[3KnYYPld{BxOjFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 MmPGNlEyPjh|OUG=
JVM-2  NUnheJVxTnWwY4Tpc44hSXO|YYm= M4fOSlMxKM7:TR?= MmS4NlQhcA>? Mn\M[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:w M33CelIyOTZ6M{mx
KBM3/Bu2506 NF;hWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXud4xRUUN{ME2wMlY4KML3TR?= MYmyNFk{OzVyOR?=
KBM3/Bu2506 M{LzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMlYh|ryP MYKyOEBp M13PeIlv[3KnYYPld{B1cGViY3XscEBnemGldHnvckBqdiCVLYDoZZNm NY\PfoxZOjB7M{O1NFk>
MDA-MB-231 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvNN2RKSzVyPUSuNEDPxE1? NUTZe3czOjB2NEezPVA>
MCF-7 NEX2VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHhbIZKSzVyPUG1MlAh|ryP M3HrZVIxPDR5M{mw
HLE-B3  M2rCXmZ2dmO2aX;uJGF{e2G7 Ml7rNlUh|ryP NUf6VlN{PDhiaB?= MlHtZoxw[2u|IFnGUk3Pu+LCk3nu[JVk\WRiU2TBWFEheGixc4Doc5J6dGG2aX;uJIFv\CCLRF:g[ZhxemW|c3nvci=> MYGyNFQ{PTF3OB?=
K562 NEXnZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqxTY5KPzJiaB?= MVfJR|UxRTNwMzDuUS=> NFPFUHYzODNyN{G5PC=>
BW-225 M4nr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHXR|U5UUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> M4TuflE5PjZzM{iw
OH-65 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi1dFJXUUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> NVSwcIRIOTh4NkGzPFA>
GR-145 M2O0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3uOIJtUUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA> NF2yfnYyQDZ4MUO4NC=>
A549 M4PwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|IxRTVwNEigx7chOTEkiKK4JO69VcLi NUH6fVhOOTh4NkGzPFA>
CaSki  MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXscHd{UUN{ME2xMlM4KMPZIEGw5qiTPyEQvF5CpC=> MWWxPFY3OTN6MB?=
ZMK-1 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7t[4pKSzJyPUGuN|chy5diMUFijLI3KM7:TdMg M{DFWFE5PjZzM{iw
SKW6.4 M2LxPGFxd3C2b4Ppd{BCe3OjeR?= NEHLeokxNjBzLUGwJO69VQ>? MkTUNlQwPDhiaB?= NE\RZWdqdmS3Y3XzJINmdGxiZHXheIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MXGxPFA6OjN2MB?=
RPMI 8226 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6yOEBp MYjJR|UxRTFwNUVCpO69VQ>? MnzXNVc6PzZzOE[=
MM.1S MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX30UmxFPDhiaB?= M2LpXmlEPTB;MUOuOFjDqM7:TR?= M2rrXlE4QTd4MUi2
MM.1R M2[yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKyOlk1QCCq MWXJR|UxRTN|Lke5JO69VQ>? M2LQU|E4QTd4MUi2
U937 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzqPYlFUUN3ME2zMFIxOCEEsTC1OlAhdk1? NX7zbWpKOTV7M{CzOlE>

... Click to View More Cell Line Experimental Data

In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01503242 Active not recruiting Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) January 9 2012 Phase 1
NCT03159702 Recruiting Hematological Malignancy Undergoing a Related Donor Haploidentical HCT|Leukemia|Multiple Myeloma|Lymphoma Medical College of Wisconsin December 8 2017 Phase 2
NCT03333486 Recruiting Accelerated Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|Aplastic Anemia|B-Cell Non-Hodgkin Lymphoma|CD40 Ligand Deficiency|Chronic Granulomatous Disease|Chronic Leukemia in Remission|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Congenital Amegakaryocytic Thrombocytopenia|Congenital Neutropenia|Congenital Pure Red Cell Aplasia|Glanzmann Thrombasthenia|Immunodeficiency Syndrome|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Paroxysmal Nocturnal Hemoglobinuria|Plasma Cell Myeloma|Polycythemia Vera|Recurrent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Severe Aplastic Anemia|Shwachman-Diamond Syndrome|Sickle Cell Disease|T-Cell Non-Hodgkin Lymphoma|Thalassemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome Roswell Park Cancer Institute|National Cancer Institute (NCI) December 7 2017 Phase 2
NCT00448201 Completed Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) January 7 2011 Phase 2
NCT00474747 Completed Aplastic Anemia M.D. Anderson Cancer Center|National Heart Lung and Blood Institute (NHLBI)|National Cancer Institute (NCI) February 7 2006 Phase 1|Phase 2
NCT03494569 Recruiting Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia|Acute Myeloid Leukemia in Remission|Hematopoietic Cell Transplantation Recipient|Minimal Residual Disease|Myelodysplastic Syndrome|Secondary Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) July 6 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID